Association of OPN rs11730582 polymorphism with cancer risk: a meta-analysis

Lanlan He; Yong Wang

doi:10.2147/OTT.S94425

Association of OPN rs11730582 polymorphism with cancer risk: a meta-analysis

Onco Targets Ther. 2016 Mar 7:9:1275-80. doi: 10.2147/OTT.S94425. eCollection 2016.

Authors

Lanlan He¹, Yong Wang²

Affiliations

¹ Emergency Department, Zhenjiang First People's Hospital, Zhenjiang, People's Republic of China.
² Department of Interventional Radiology and Vascular Surgery, Zhongda Hospital, Southeast University, Nanjing, Jiangsu, People's Republic of China.

Abstract

Purpose: Several molecular epidemiological studies have investigated the association between OPN rs11730582 C>T polymorphism and cancer risk, but the results are inconsistent. Hence, a meta-analysis was conducted to determine the association of this polymorphism with cancer risk.

Materials and methods: The related articles were searched in PubMed, Embase, and Chinese National Knowledge Infrastructure databases. Pooled odds ratios and 95% confidence intervals were calculated to evaluate the strength of the associations. A random-effects model or fixed-effects model was employed depending on the heterogeneity.

Results: A total of ten case-control studies involving 2,749 cancer cases and 3,398 controls were included in the meta-analysis. In overall analysis, OPN rs11730582 C.T polymorphism was not associated with cancer risk. In a stratified analysis by cancer type, no significant association was found between OPN rs11730582 C>T polymorphism and the risk of glioma, gastric cancer, and other cancers.

Conclusion: This meta-analysis suggests that OPN rs11730582 C.T polymorphism is not associated with cancer susceptibility.

Keywords: cancer; osteopontin; polymorphism; risk.